AstraZeneca slides after reports of Bristol Myers merger talks leave analysts ‘perplexed’
AstraZeneca shares dropped on Monday after reports that the company had discussed a potential mega-merger with Bristol Myers Squibb, a deal that analysts said would be a surprising strategic move for one of the pharmaceutical industry’s strongest growth stories.
CNBC’s Annika Kim Constantino explains.
